Flow diversion for the management of intracranial aneurysms represents a paradigm shift in how aneurysms are managed. The Pipeline embolization device (PED) is, to date, the only flow diverter approved for use in the USA by the Food and Drug Administration. Limitations and complications with new treatment strategies are inevitable, and with the PED there have been reports of complications, most commonly with challenging deployments. Once deployment has been initiated, the device is 'one-way'; it can only be deployed further or removed. Yet, situations arise in which the ability to recapture or reposition the device would be advantageous. A second-generation Pipeline has been developed that addresses these concerns. We report the first use in North America of this second-generation Pipeline device: the Pipeline Flex. We discuss our rationale for using the device, our impressions of its operation, and the relevant literature concerning the current state of flow diversion.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/neurintsurg-2014-011548.rep | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Flex vs. Vantage Pipeline™ Flow Diverters: Technical analysis in treating complex fusiform basilar artery aneurysm.
Interv Neuroradiol
January 2025
Department of Neurology, University of Chicago, Chicago, IL, USA.
We present a case of an adult patient with a large symptomatic fusiform basilar artery aneurysm. This video demonstrates the ease of deploying the new Pipeline™ Vantage Flow Diverter compared to the Flex model in the same vessel. The Flex and Vantage have different deployment techniques-as using the Flex maneuvering technique on the Vantage may damage the braid.
View Article and Find Full Text PDFImplementation of Integrated Clinical Pharmacogenomics Testing at an Academic Medical Center.
J Appl Lab Med
December 2024
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Background: Pharmacogenomics has demonstrated benefits for clinical care, including a reduction in adverse events and cost savings. However, barriers in expanded implementation of pharmacogenomics testing include prolonged turnaround times and integration of results into the electronic health record with clinical decision support. A clinical workflow was developed and implemented to facilitate in-house result generation and incorporation into the electronic health record at a large academic medical center.
View Article and Find Full Text PDFEvaluation of aneurysm flow divertor (stent) treatment using multi-angled 1000 fps High-Speed Angiography (HSA) and Optical Flow (OF).
Proc SPIE Int Soc Opt Eng
February 2024
University of Buffalo, Buffalo, New York, USA; Canon Research Stroke and Vascular Center, Buffalo, New York, USA; Florida Institute of Technology, Melbourne, Florida.
Understanding detailed hemodynamics is critical in the treatment of aneurysms and other vascular diseases; however, traditional digital subtraction angiography (DSA) does not provide detailed quantitative flow information. Instead, 1000 fps High-Speed Angiography (HSA) can be used for high-temporal visualization and evaluation of detailed blood flow patterns and velocity distributions. In the treatment of aneurysms, flow diverter expansion and positioning play a critical role in affecting the hemodynamics and optimal patient outcomes.
View Article and Find Full Text PDFSafety and efficacy of coated flow diverters in the treatment of cerebral aneurysms during single antiplatelet therapy: A multicenter study.
Interv Neuroradiol
December 2024
University of Cologne, Faculty of Medicine and University Hospital, Department of Radiology and Neuroradiology, Cologne, Germany.
Article Synopsis
- This study analyzed the safety and effectiveness of coated flow diverters (cFDs) for treating cerebral aneurysms while patients were on single antiplatelet therapy (SAPT).
- It involved 41 patients with a median age of 58, noting a low complication rate with only 5% experiencing early ischemic issues, and no complications reported after four months for most patients.
- The results suggest that using cFDs under SAPT shows a promising occlusion rate (75% complete, 89% favorable) and calls for further research through prospective trials.
Premise: Detecting single-nucleotide polymorphisms (SNPs) in a cost-effective way is fundamental in any plant breeding pipeline. Here, we compare three genotyping techniques for their ability to reproduce the allele dosage of SNPs of interest in sugarcane ( spp.).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!